TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32340423

Group type: EXPERIMENTAL
Intervention: Scenario infiltration joint interactive training (SIJIT)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Routine training (RT)
Number of subjects: 118
Study: 32594786

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide 2.5 mg/ml
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Betamethasone 1.75 mg/ml
Number of subjects: 12

Group type: COMPARATOR
Intervention: Betamethasone 0.375 mg/ml
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 12
Study: 33393476

Group type: EXPERIMENTAL
Intervention: PanCan model
Number of subjects: 6956

Group type: COMPARATOR
Intervention: Lung-RADS
Number of subjects: 6956

Group type: EXPERIMENTAL
Intervention: Risk-gap nodules (n=543)
Number of subjects: 6956

Group type: EXPERIMENTAL
Intervention: PanCan model and Lung-RADS
Number of subjects: 6956
Study: 34815165

Group type: EXPERIMENTAL
Intervention: SMS reminders for medication intake (first to seventh postoperative days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no SMS reminders)
Number of subjects: 0
Study: 33166497

Group type: EXPERIMENTAL
Intervention: Personalised dosimetry (≥205 Gy targeted to the index lesion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard dosimetry (120 ± 20 Gy targeted to the perfused lobe)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Personalised dosimetry
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard dosimetry
Number of subjects: 60
Study: 32874061

Group type: EXPERIMENTAL
Intervention: Chinese herbal formula
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study: 35272967

Group type: EXPERIMENTAL
Intervention: Posterior rhabdosphincter reconstruction (PRR)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control arm (single urethrovesical anastomosis)
Number of subjects: 152
Study: 32031973

Group type: EXPERIMENTAL
Intervention: Education program based on the health belief model (HBM) in four 75-min sessions
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study: 34468869

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg Q3W for up to 35 cycles
Number of subjects: 395

Group type: COMPARATOR
Intervention: Paclitaxel (standard-dose)
Number of subjects: 395
Study: 33308290

Group type: EXPERIMENTAL
Intervention: Biweekly debriefing sessions facilitated by a psychotherapist for 3 months
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control arm without debriefing sessions
Number of subjects: 200
Study: 32937016

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33864481

Group type: EXPERIMENTAL
Intervention: Neck‐worn position therapy device (PTD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral appliance (OA)
Number of subjects: 0
Study: 32808484

Group type: EXPERIMENTAL
Intervention: 35% calorie-reduced (CR) diet
Number of subjects: 60

Group type: COMPARATOR
Intervention: Weight-maintaining energy needs (WMEN) diet
Number of subjects: 60
Study: 33103499

Group type: EXPERIMENTAL
Intervention: Arabic smartphone application 'My Dear Knee' (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Paper hand-outs (control; n=20)
Number of subjects: 40
Study: 33223499

Group type: EXPERIMENTAL
Intervention: Covered self-expandable metal stents (CSEMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uncovered self-expandable metal stents (UCSEMS)
Number of subjects: 0
Study: 35001638

Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Tadalafil
Number of subjects: 20
Study: 33992879

Group type: EXPERIMENTAL
Intervention: Cooperative learner simulation order (LSO)
Number of subjects: 81
Study: 35946024

Group type: EXPERIMENTAL
Intervention: Isoflurane (n = 20)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sevoflurane (n = 20)
Number of subjects: 40
Study: 32560746

Group type: EXPERIMENTAL
Intervention: Dornase alfa (Pulmozyme®, Roche, Switzerland) administered by aerosol, at a dose of 2500 IU twice daily for 7 consecutive days.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual care without aerosols (control group).
Number of subjects: 100
Study: 34318430

Group type: EXPERIMENTAL
Intervention: Cerebellar anodal transcranial direct current stimulation (atDCS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham intervention
Number of subjects: 20
Study: 33351479

Group type: EXPERIMENTAL
Intervention: High impact journals (impact factor >3)
Number of subjects: 1044

Group type: EXPERIMENTAL
Intervention: Advanced statistical analysis
Number of subjects: 1044

Group type: COMPARATOR
Intervention: Medium impact journals (impact factor 1-3)
Number of subjects: 1044

Group type: COMPARATOR
Intervention: Low impact journals (impact factor <1)
Number of subjects: 1044
Study: 32539568

Group type: EXPERIMENTAL
Intervention: Implantation of decellularized matrix seeded with autologous bone marrow-derived nucleated cells (BMNCs)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Implantation of decellularized matrix without BMNCs
Number of subjects: 8
Study: 35351187

Group type: EXPERIMENTAL
Intervention: App-based intervention (Active 10) supplemented with habit-based behavioural support (two brief telephone/video calls, an information leaflet, and walking planners)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: App-based intervention (Active 10) supplemented with habit-based behavioural support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative interviews
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accelerometer measured average daily minutes of brisk walking (≥ 100 steps/min)
Number of subjects: 0
Study: 36433662

Group type: EXPERIMENTAL
Intervention: Bioactive collagen peptides (CP) 15 g daily
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 39
Study: 34494525

Group type: EXPERIMENTAL
Intervention: Mobile health management
Number of subjects: 295

Group type: COMPARATOR
Intervention: Traditional management
Number of subjects: 295
Study: 32946715

Group type: EXPERIMENTAL
Intervention: Systematic procedure for inferring neuronal couplings using a binary statistical model (Ising or generalized McCulloch-Pitts model)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimal time bin size determination based on null hypothesis of independent firing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postprocessing step comparing original estimates with randomized data sets
Number of subjects: 0
Study: 33615992

Group type: EXPERIMENTAL
Intervention: Vitamin C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin B2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34535037

Group type: EXPERIMENTAL
Intervention: Apixaban 2.5 mg bid
Number of subjects: 1722

Group type: COMPARATOR
Intervention: Apixaban 5 mg bid
Number of subjects: 1722

Group type: EXPERIMENTAL
Intervention: Both doses of apixaban
Number of subjects: 1722
Study: 32459597

Group type: EXPERIMENTAL
Intervention: Atezolizumab, carboplatin, and paclitaxel (ACP)
Number of subjects: 1187

Group type: EXPERIMENTAL
Intervention: Atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP)
Number of subjects: 1187

Group type: COMPARATOR
Intervention: Bevacizumab, carboplatin, and paclitaxel (BCP)
Number of subjects: 1187

Group type: EXPERIMENTAL
Intervention: All treatment arms (ACP, ABCP, BCP)
Number of subjects: 1187
Study: 32468730

Group type: EXPERIMENTAL
Intervention: Extended Sleep Opportunity (ESO) by 90 minutes per night
Number of subjects: 32

Group type: COMPARATOR
Intervention: Typical Sleep Opportunity (TSO)
Number of subjects: 32
Study: 34823952

Group type: EXPERIMENTAL
Intervention: Nano-fluoro dispersion functionalized silk
Number of subjects: 0
Study: 34114630

Group type: EXPERIMENTAL
Intervention: Open surgical exposure
Number of subjects: 120

Group type: COMPARATOR
Intervention: Closed surgical exposure
Number of subjects: 120
Study: 32386271

Group type: EXPERIMENTAL
Intervention: Bipolar sealing device (BSD) with suture augmentation (4-0 polydioxanone)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Bipolar sealing device (BSD) without suture augmentation
Number of subjects: 23
Study: 33888517

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes diagnosed at age <45 years
Number of subjects: 101080

Group type: COMPARATOR
Intervention: Matched control subjects
Number of subjects: 101080
Study: 33325259

Group type: EXPERIMENTAL
Intervention: HI-FIVES intervention (three weekly facilitated training calls covering five education topics)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: HI-FIVES intervention
Number of subjects: 118
Study: 36441735

Group type: EXPERIMENTAL
Intervention: Health Belief Model‐Based Intervention (HEBI)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Health talk on non-communicable disease (Control)
Number of subjects: 284
Study: 33836878

Group type: EXPERIMENTAL
Intervention: Tocilizumab at 8 mg/kg on day -1 and abatacept at 10 mg/kg on days 0, 7, 14, and 28
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: mDLI starting on day 0
Number of subjects: 149

Group type: COMPARATOR
Intervention: Historical cohort received rabbit ATG at 5 mg/kg total dose
Number of subjects: 149

Group type: COMPARATOR
Intervention: Historical cohort
Number of subjects: 149
Study: 32828682

Group type: EXPERIMENTAL
Intervention: Intraoperative application of a penile tourniquet
Number of subjects: 110

Group type: COMPARATOR
Intervention: No intraoperative application of a penile tourniquet
Number of subjects: 110
Study: 36449023

Group type: EXPERIMENTAL
Intervention: CEA with 3-6 cm incision (Group A)
Number of subjects: 730

Group type: COMPARATOR
Intervention: CEA with >6 cm incision (Group B)
Number of subjects: 730
Study: 33020939

Group type: EXPERIMENTAL
Intervention: Comorbidity-based delirium risk index (DRI) derived from 14 comorbidities with weights ranging from 1 to 6.
Number of subjects: 1636007

Group type: COMPARATOR
Intervention: Charlson-Deyo Comorbidity Index
Number of subjects: 1636007
Study: 35618331

Group type: EXPERIMENTAL
Intervention: Standardised Patient (SP) role play
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peer role play
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (SP and Peer)
Number of subjects: 0
Study: 33810804

Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation (TTNS) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 0
Study: 32218096

Group type: EXPERIMENTAL
Intervention: Isavuconazonium sulfate (ISA) for ≥7 days
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Isavuconazonium sulfate (ISA)
Number of subjects: 18
Study: 35138211

Group type: EXPERIMENTAL
Intervention: Complex Skill Group (CSG) - focused on acquisition of running, n = 13
Number of subjects: 41

Group type: COMPARATOR
Intervention: Simple Skill Group (SSG) - focused on locomotion, n = 15
Number of subjects: 41
Study: 34159231

Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical stimulation (TAES) applied to four acupoints (Tianshu, Quchi, Zusanli, Shangjuxu), six times a week for 4 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Transcutaneous acupoint electrical stimulation (TAES)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study: 32412598

Group type: EXPERIMENTAL
Intervention: Theracurmin® (360 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 33450748

Group type: EXPERIMENTAL
Intervention: NSMD + PT
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: NSMD + AT
Number of subjects: 42

Group type: COMPARATOR
Intervention: NSMD alone
Number of subjects: 42
Study: 33245618

Group type: EXPERIMENTAL
Intervention: Your Path to Transplant (YPT)
Number of subjects: 802

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 802
Study: 35062886

Group type: EXPERIMENTAL
Intervention: 1–2–3 group receiving 0.25 g/d methylprednisolone intravenously for 3 consecutive days in the 1st‐2nd‐3rd months and oral prednisone 0.5 mg/kg/d for 6 months
Number of subjects: 68

Group type: COMPARATOR
Intervention: 1–3–5 group receiving the same intravenous methylprednisolone treatment in the 1st‐3rd‐5th months and the same oral prednisone
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 1–2–3 group
Number of subjects: 68

Group type: COMPARATOR
Intervention: 1–3–5 group
Number of subjects: 68
Study: 32066290

Group type: EXPERIMENTAL
Intervention: Individualized written asthma action plan (WAAP)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Standard discharge instructions
Number of subjects: 91
Study: 33462653

Group type: EXPERIMENTAL
Intervention: Annual zoledronic acid (ZOL) infusion (5 mg) at 1 week, 12 months, and 24 months after surgery
Number of subjects: 154

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study: 35922187

Group type: EXPERIMENTAL
Intervention: Complete care
Number of subjects: 27192

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 27192

Group type: EXPERIMENTAL
Intervention: Third study year
Number of subjects: 27192
Study: 33340238

Group type: COMPARATOR
Intervention: TRK‐100STP 240 μg
Number of subjects: 339

Group type: COMPARATOR
Intervention: TRK‐100STP 120 μg
Number of subjects: 339
Study: 32718943

Group type: EXPERIMENTAL
Intervention: Aspirin 81 mg/day
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Aspirin 325 mg/day
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 35771961

Group type: EXPERIMENTAL
Intervention: Screening group (offered prostate specific antigen testing every 2 years)
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Control group (not offered screening)
Number of subjects: 20000
Study: 34021033

Group type: COMPARATOR
Intervention: TIL alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: TIL + DC
Number of subjects: 18
Study: 36374501

Group type: EXPERIMENTAL
Intervention: Vaginal estradiol tablet (10 μg/d for 2 weeks and then twice weekly) plus placebo gel (3 times weekly)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Dual placebo
Number of subjects: 174
Study: 33016987

Group type: EXPERIMENTAL
Intervention: Asthma Basic Care (ABC) family education combined with Head Start asthma education
Number of subjects: 398

Group type: COMPARATOR
Intervention: Head Start asthma education alone
Number of subjects: 398
Study: 33492523

Group type: EXPERIMENTAL
Intervention: Favipiravir
Number of subjects: 96

Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 96
Study: 32272518

Group type: EXPERIMENTAL
Intervention: Calcium hydroxylapatite (CaHA) diluted with normal saline (1:2) injected subdermally
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Microfocused ultrasound with visualization (MFU-V)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of CaHA and MFU-V
Number of subjects: 20
Study: 35074830

Group type: EXPERIMENTAL
Intervention: Basic bladder advice (voiding and drinking according to a strict schedule and instructions regarding toilet posture)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Enuresis alarm therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 60
Study: 33214022

Group type: EXPERIMENTAL
Intervention: Nomogram incorporating five feature variables: PCI timing after hospitalization, ejection fraction (EF), high-sensitive troponin T (hsTnT) score, infection, and estimated glomerular filtration rate (eGFR).
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Nomogram with five variables for predicting VTA risk.
Number of subjects: 503
Study: 32278339

Group type: EXPERIMENTAL
Intervention: Bulk-filled composite resins with etch-and-rinse, self-etch, or selective-etch protocols
Number of subjects: 96

Group type: COMPARATOR
Intervention: Conventional composites with etch-and-rinse, self-etch, or selective-etch protocols
Number of subjects: 96
Study: 34397205

Group type: EXPERIMENTAL
Intervention: guselkumab 100 mg every-8-weeks
Number of subjects: 1721
Study: 36263546

Group type: EXPERIMENTAL
Intervention: Ligasure vessel sealing system (LVSS)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Conventional knot tying
Number of subjects: 68
Study: 32602793

Group type: EXPERIMENTAL
Intervention: Blackcurrant extract (300 mg/d, 105 mg/d anthocyanin)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 32243717

Group type: EXPERIMENTAL
Intervention: StressProffen (app-based intervention)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 172
Study: 36266534

Group type: COMPARATOR
Intervention: captopril/placebo
Number of subjects: 50

Group type: COMPARATOR
Intervention: telmisartan/placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: captopril + telmisartan
Number of subjects: 50

Group type: COMPARATOR
Intervention: placebo/placebo
Number of subjects: 50
Study: 34916637

Group type: EXPERIMENTAL
Intervention: Sealing group (RMGIC without caries removal)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Restoration group (RMGIC with selective caries removal)
Number of subjects: 93
Study: 32747412

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 19114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19114

Group type: COMPARATOR
Intervention: Not on aspirin
Number of subjects: 19114
Study: 35408390

Group type: EXPERIMENTAL
Intervention: Cognitive task (counting down in threes from a randomly assigned number between 95 and 100) during mCTSIB
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cognitive task during mCTSIB
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Postural sway jerk
Number of subjects: 10
Study: 32866850

Group type: EXPERIMENTAL
Intervention: HDM allergen positive patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: All patients (including HDM positive and negative)
Number of subjects: 100
Study: 35063007

Group type: EXPERIMENTAL
Intervention: Same day discharge with ongoing telemonitoring up to 7 days after surgery
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard of in-hospital care with discharge on the first postoperative day
Number of subjects: 200
Study: 36041758

Group type: EXPERIMENTAL
Intervention: ASICA intervention (tablet-based intervention designed to support monthly TSSE)
Number of subjects: 104
Study: 32705811

Group type: COMPARATOR
Intervention: Counselling from care providers about nutrition and physical activity
Number of subjects: 66

Group type: COMPARATOR
Intervention: Women's beliefs and values regarding weight gain
Number of subjects: 66

Group type: COMPARATOR
Intervention: Access to information on safe physical activity in pregnancy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Competing priorities
Number of subjects: 66

Group type: COMPARATOR
Intervention: Pregnancy symptoms (fatigue and nausea)
Number of subjects: 66
Study: 35831082

Group type: EXPERIMENTAL
Intervention: Short list of essential medicines provided free of charge
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Short list of essential medicines
Number of subjects: 379
Study: 35578276

Group type: EXPERIMENTAL
Intervention: Digital alcohol intervention
Number of subjects: 2129

Group type: COMPARATOR
Intervention: Alcohol information (control)
Number of subjects: 2129
Study: 33836963

Group type: EXPERIMENTAL
Intervention: Regional anesthesia (R group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Local anesthesia (L group)
Number of subjects: 80
Study: 34153231

Group type: EXPERIMENTAL
Intervention: High-dose induction adalimumab (2·4 mg/kg at weeks 0 and 1)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Standard-dose induction adalimumab (2·4 mg/kg at week 0 and placebo at week 1)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: High-dose maintenance adalimumab (0·6 mg/kg weekly)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Standard-dose maintenance adalimumab (0·6 mg/kg every other week)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Pooled adalimumab groups (high-dose and standard-dose)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo (external comparison)
Number of subjects: 93
Study: 34779246

Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 441

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study: 32972404

Group type: EXPERIMENTAL
Intervention: Individualized video feedback (IVF)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Unsupervised video feedback (UVF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Direct expert feedback (DEF)
Number of subjects: 60
Study: 35057489

Group type: EXPERIMENTAL
Intervention: 11 g of BiotisTM GOS
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 5.5 g of BiotisTM GOS
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control product
Number of subjects: 132
Study: 34117528

Group type: EXPERIMENTAL
Intervention: 3× weekly bicycle ergometer training during HD for 12 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: No training during HD for 12 weeks (control group)
Number of subjects: 54
Study: 33152450

Group type: EXPERIMENTAL
Intervention: artemisinin-piperaquine (AP)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control
Number of subjects: 41

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 41
Study: 34473842

Group type: EXPERIMENTAL
Intervention: WaveOne Gold (size 35, .06 taper)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TRUShape (size 30, .06v taper)
Number of subjects: 30

Group type: COMPARATOR
Intervention: XP‐endo Shaper
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: WaveOne Gold
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: TRUShape
Number of subjects: 30
Study: 32371534

Group type: EXPERIMENTAL
Intervention: Bilateral subthalamic nucleus deep brain stimulation (STN-DBS)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Standard-of-care medical treatment (MED)
Number of subjects: 151
Study: 34967863

Group type: EXPERIMENTAL
Intervention: Multimedia patient education platform
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional patient education methods via clinical visits
Number of subjects: 100
Study: 34294842

Group type: EXPERIMENTAL
Intervention: Preservative-free latanoprost
Number of subjects: 51

Group type: COMPARATOR
Intervention: Preserved latanoprost
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51